JBIO
Jade Biosciences, Inc. NASDAQ Listed Apr 29, 2025$16.82
-0.30%
vs $16.87
Mkt Cap $527.5M
52w Low $6.77
50.0% of range
52w High $26.85
50d MA $21.22
200d MA $14.65
P/E (TTM)
-4.1x
EV/EBITDA
—
P/B
1.6x
Debt/Equity
0.0x
ROE
-38.3%
P/FCF
-5.6x
RSI (14)
30.70
ATR (14)
$1.63
Beta
1.03
50d MA
$21.22
200d MA
$14.65
Avg Volume
1.1M
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
221 Crescent Street Building 23 · Waltham, MA 02453 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | AMC | -0.45 | -0.11 | +75.6% | 14.05 | +2.8% | +2.7% | +0.3% | -3.2% | -1.1% | +0.4% | — |
| Nov 13, 2025 | AMC | -0.57 | -0.48 | +15.8% | 9.68 | -0.8% | +10.5% | +17.7% | +0.5% | -1.5% | -7.9% | — |
| Aug 13, 2025 | AMC | -0.43 | -0.86 | -100.0% | 7.33 | +5.9% | -7.6% | +8.7% | +1.9% | -1.9% | -6.9% | — |
| Apr 25, 2025 | AMC | -8.40 | -0.09 | +98.9% | 93.80 | -0.7% | +0.0% | -89.2% | -6.3% | +5.3% | +24.8% | — |
| Mar 27, 2025 | AMC | -0.19 | -0.19 | +0.0% | 88.55 | +0.8% | +0.0% | -0.8% | +0.0% | +0.4% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15 | UBS | Initiates | Buy | $45 | $15.34 | $16.00 | +4.3% | +5.0% | -3.5% | +8.6% | -0.3% | — |
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.98 | $25.78 | +3.2% | +7.5% | -1.5% | -15.6% | +9.3% | -0.7% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.26 | $13.58 | +2.4% | +5.2% | +0.0% | -4.0% | -1.0% | +6.0% |
| Mar 16 | BTIG | Maintains | Buy → Buy | — | $13.92 | $14.79 | +6.2% | +2.4% | -2.0% | -1.4% | +2.2% | -0.6% |
| Mar 11 | Guggenheim | Maintains | Buy → Buy | — | $14.48 | $14.90 | +2.9% | -3.2% | -1.1% | +0.4% | +2.4% | -2.0% |
| Mar 9 | Wedbush | Maintains | Outperform → Outperform | — | $14.05 | $14.44 | +2.8% | +2.7% | +0.3% | -3.2% | -1.1% | +0.4% |
| Nov 18 | Guggenheim | Maintains | Buy → Buy | — | $12.59 | $12.84 | +2.0% | +0.5% | -1.5% | -7.9% | +4.5% | +1.3% |
| Aug 14 | Wedbush | Maintains | Outperform → Outperform | — | $7.33 | $7.76 | +5.9% | -7.6% | +8.7% | +1.9% | -1.9% | -6.9% |
| Jun 16 | Guggenheim | Upgrade | Neutral → Buy | — | $6.76 | $7.25 | +7.2% | +3.4% | +18.6% | +13.5% | +5.1% | -0.2% |
| May 15 | Wedbush | Maintains | Outperform → Outperform | — | $7.55 | $7.50 | -0.7% | -2.0% | -0.8% | +1.1% | +4.0% | -3.0% |
No insider trades available.
8-K · 7.01
! Medium
Jade Biosciences, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 1
8-K · 2.02
!! High
Jade Biosciences, Inc. -- 8-K 2.02: Earnings Results
Jade Biosciences reported earnings results; investors should review the complete press release filed as Exhibit 99.1 for detailed financial performance and guidance information.
May 7
8-K
Jade Biosciences, Inc. -- 8-K Filing
I cannot provide a meaningful analysis from this filing summary, as it contains only standard incorporation and address information without disclosing any material business events or transactions affecting Jade Biosciences investors.
Apr 22
8-K
Unknown — 8-K Filing
Jeanerette BioVentures is implementing a 2026 equity incentive plan to attract new employees, signaling management confidence in growth plans but potentially diluting existing shareholders through future stock issuances.
Apr 2
8-K
Jade Biosciences, Inc. -- 8-K Filing
Jade Biosciences (JBIO) advanced its clinical pipeline in 2025 by initiating a Phase 1 study for JADE101 and progressing JADE201 toward clinical development, signaling continued pipeline momentum for its autoimmune disease therapies.
Mar 6
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 7,085,423 | $100M | Added | Mar 2026 |
| 2 | Fairmount Funds Management Llc | 4,553,494 | $64M | — | Mar 2026 |
| 3 | Vr Adviser, Llc | 3,220,364 | $50M | — | Dec 2025 |
| 4 | Bellevue Group Ag | 3,501,502 | $49M | Added | Mar 2026 |
| 5 | Remedium Capital Partners, Llc | 3,155,500 | $44M | — | Mar 2026 |
| 6 | Janus Henderson Group Plc | 3,105,669 | $44M | New | Mar 2026 |
| 7 | Vanguard Capital Management Llc | 1,796,652 | $25M | New | Mar 2026 |
| 8 | Avidity Partners Management Lp | 1,400,708 | $20M | New | Mar 2026 |
| 9 | Samsara Biocapital, Llc | 968,798 | $15M | Added | Dec 2025 |
| 10 | Marshall Wace, Llp | 944,776 | $13M | Added | Mar 2026 |
| 11 | Aberdeen Group Plc | 867,284 | $12M | — | Mar 2026 |
| 12 | Soleus Capital Management, L.p. | 796,744 | $11M | — | Mar 2026 |
| 13 | Rtw Investments, Lp | 573,205 | $8M | Reduced | Mar 2026 |
| 14 | Opaleye Management Inc. | 427,608 | $7M | New | Dec 2025 |
| 15 | Caption Management, Llc | 297,095 | $5M | New | Dec 2025 |
| 16 | Point72 Asset Management | 264,315 | $4M | Reduced | Mar 2026 |
| 17 | Northern Trust Corp | 241,905 | $3M | Reduced | Mar 2026 |
| 18 | Vanguard Portfolio Management Llc | 211,319 | $3M | New | Mar 2026 |
| 19 | Morgan Stanley | 159,534 | $2M | Added | Dec 2025 |
| 20 | Millennium Management | 160,051 | $2M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$527.5M
Enterprise Value
$191.3M
P/E (TTM)
-4.14x
Forward P/E
—
PEG Ratio
0.04x
P/B
1.59x
P/S
—
P/FCF
-5.56x
EV/EBITDA
—
Shares Out
31.4M
Financials (TTM)
Revenue
$0
Net Income
-$127.4M
EBITDA
-$113.5M
Free Cash Flow
-$94.9M
Op Cash Flow
-$94.7M
EPS Basic
$-4.06
EPS Diluted
$-4.06
EPS Forward
$-2.10
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$349.8M
Total Liab.
$17.3M
Total Equity
$332.5M
Cash
$336.2M
LT Debt
$0
Book Value/Sh
$10.60
Debt/Equity
0.00x
Current Ratio
20.33
Quick Ratio
20.33
Returns & Growth
ROE
-38.3%
ROA
-36.4%
ROIC
-34.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+95.2%
Price Returns
2W
-12.8%
1M
-13.8%
3M
+41.9%
6M
+64.1%
12M
+190.2%
Technicals
52W High
$26.85
52W Low
$6.77
50d MA
$21.22
200d MA
$14.65
RSI (14)
30.70
ATR (14)
$1.63
Beta
1.03
Avg Volume
1.1M
Dividends
Div Rate
$2.40
Div Yield
9.9%
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$42.50
High
$45.00
Low
$40.00
Median
$42.50
Data updated apr 25, 2026 4:43pm
· Source: financialmodelingprep.com